Clinical Trial

Safety and Efficacy of NK510 to Treat NSCLC

Recruiting Early Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated May 20, 2026 (before its estimated July 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
This study assesses the safety and efficacy of NK510 combined with PD-(L)1 inhibitors for relapsed/refractory advanced NSCLC, with two administration routes: intravenous infusion and intrapleural perfusion for malignant pleural effusion. Eligible patients need confirmed measurable lesions; intravenous cohort requires EGFR/ROS1/ALK negativity and disease progression after PD-(L)1 inhibitor treatment, while intrapleural cohort accepts targeted therapy-resistant patients with ≥500ml pleural effusion, and the treatment's safety, efficacy and immune microenvironment changes will be evaluated.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2023-10-17; most recent amendment 2026-05-18.
Trial Details
NCT Number NCT06097962
Lead Sponsor Base Therapeutics (Shanghai) Co., Ltd.
Collaborators: Jinling Hospital, China
Conditions NSCLC
Enrollment 12 participants
Start Date 2023-07-01
Primary Completion 2026-07-01 (estimated)
Study Completion 2026-07-01 (estimated)
Updated on ClinicalTrials.gov 2026-05-20